TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura

TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura

Inclusion criteria for randomization included 6 - 14 days of migraine per month as assessed by a headache specialist, and failure (either lack of efficacy or intolerance) of 3 preventive medications and a significant right to left cardiac shunt (Spencer grade 4-5) determined by a screening TransCran...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2015-10, Vol.66 (15), p.B13-B13
Hauptverfasser: Tobis, Jonathan, Charles, Andrew, Silberstein, Stephen D, Sorensen, Sherman, Maini, Brij, Horwitz, Phillip A, Gurley, John c
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cardiovascular
Headaches
Internal Medicine
Migraine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Inclusion criteria for randomization included 6 - 14 days of migraine per month as assessed by a headache specialist, and failure (either lack of efficacy or intolerance) of 3 preventive medications and a significant right to left cardiac shunt (Spencer grade 4-5) determined by a screening TransCranial Doppler (TCD) intravenous agitated saline study.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2015.08.076